A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

• Citrate-Free Mirikizumab (Drug), also known as LY3074828: Administered SC

Primary outcomes

• Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab [Day 1: Predose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 hours post-dose.]: Cmax of Mirikizumab is reported.
• PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Mirikizumab [Day 1: Predose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 hours post-dose.]: AUC \[0-∞\] of Mirikizumab is reported.
• PK: Area Under the Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration (AUC [0-tlast]) of Mirikizumab [Day 1: Predose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704 hours post-dose.]: AUC \[0 to tlast\] of Mirikizumab is reported.

Sex: All, ages: 18 Years to 65 Years, accepts healthy volunteers

Inclusion Criteria:

Type of participant and disease characteristics

1. Overtly healthy males and females as determined by medical evaluation including:

   * Medical history,
   * Physical examination,
   * Clinical laboratory tests,
   * Electrocardiogram (ECG),
   * Vital signs

   Note: participants may have chronic, stable medical conditions that, in the investigator's opinion, will not place the participant at increased risk by participating in the study, and will not interfere with interpretation of the data.
2. Have clinical laboratory test results:

   * Within normal reference range for the population, or
   * Within normal reference range for the investigative site, or
   * Results with acceptable deviations that are judged to be not clinically significant by the investigator.

   Weight
3. Have a body mass index (BMI) within the range of 18.0 to 34.0 kilograms per milligram squared (km/m\^2), inclusive.

   Exclusion Criteria:

   Participants are excluded from the study if any of the following criteria apply:

   Medical conditions
4. Have significant allergies to humanized monoclonal antibodies or known allergies to citrate-free mirikizumab, related compounds or any components of the formulation.
5. Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data.
6. Have clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions.
7. Have a diagnosis or history of malignant disease within 5 years prior to baseline.

   Prior/concomitant therapy
8. Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing.
9. Have received treatment with biologic agents, such as monoclonal antibodies, including marketed drugs, within 3 months or 5 half-lives, whichever is longer, prior to dosing.
10. Have ever received anti-interleukin (IL)-12p40 antibodies or anti-IL-23p19 antibodies, for any indication, including investigational use.
11. Have received any live vaccine (that is, live attenuated) within less than 4 weeks or inactivated vaccine within less than 2 weeks before randomization.

    Prior/concurrent clinical study experience
12. Are currently enrolled in a clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
13. Have participated in a clinical study involving an investigational product within the last 30 days or 5 half-lives, whichever is longer, prior to screening. If the clinical trial involved treatment with biologic agents, such as monoclonal antibodies, including marketed drugs, at least 3 months or 5 half-lives, whichever is longer, should have elapsed prior to dosing.
14. Have previously completed or withdrawn from this study or any other study investigating mirikizumab, and have previously received mirikizumab.

    Diagnostic assessments
15. Have a current infection with hepatitis C virus.
16. Have a current infection with hepatitis B virus.
17. Have a current or recent acute, active infection.
18. Have had any of the following types of infection within 3 months prior to screening or develops any of these infections before the randomization:

    1. Serious: Requiring hospitalization, or intravenous (IV) or equivalent oral antibiotic treatment, or both.
    2. Opportunistic: As defined in Winthrop et al. 2015. Note: Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over.
    3. Chronic: Duration of symptoms, signs, and/or treatment of 6 weeks or longer.
    4. Recurring: Including, but not limited to, herpes simplex, herpes zoster, recurring cellulitis, chronic osteomyelitis.
19. Show evidence of active or latent tuberculosis (TB).

    Other exclusion criteria
20. Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation, or an amount deemed significant by the investigator.
21. Smoke more than 10 cigarettes per day, or equivalent, or are unable to abide by investigative site smoking restrictions.
22. In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.

Participant flow

Outcome results

• Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Mirikizumab (Primary), Geometric mean, microgram per milliliter (ug/mL): 200 mg Mirikizumab (Reference) 12.9 +/- 40; 200 mg Mirikizumab (Test) 13.5 +/- 39
• PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Mirikizumab (Primary), Geometric mean, microgram*day per milliliter (ug*day/mL): 200 mg Mirikizumab (Reference) 225 +/- 41; 200 mg Mirikizumab (Test) 228 +/- 41
• PK: Area Under the Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration (AUC [0-tlast]) of Mirikizumab (Primary), Geometric mean, microgram*day per milliliter (ug*day/mL): 200 mg Mirikizumab (Reference) 220 +/- 40; 200 mg Mirikizumab (Test) 223 +/- 41

Adverse events

Time frame: Baseline up to Day 74

Other adverse events by term

20 more terms not shown.

• Results publication: Otani Y, Payne CD, Loftus EV Jr, D'Haens G, Ben Horin S, Upadhya K A, Todd K, Pellanda P, Shi G, Zhang X. One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants. Adv Ther. 2026 Jan;43(1):377-389. doi: 10.1007/s12325-025-03422-1. Epub 2025 Nov 28. PMID 41313544

• Study Protocol (PDF, 2024-09-24)
• Statistical Analysis Plan (PDF, 2024-06-06)

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 : Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company